Yaqrit 任命董事会及高管团队成员，旨在加强融资与监管能力并为临床试验做准备

Core Insights - Yaqrit is a late-stage clinical research company focused on developing life-saving therapies for advanced liver disease, recently appointing Ronen Israel and Amrik Shah to strengthen its leadership team [1][2][4] Group 1: Leadership Appointments - Ronen Israel, a healthcare innovation expert and hedge fund strategist, has been appointed as a member of the board, bringing extensive financial and biomedical experience [1][3] - Amrik Shah has been appointed as Chief Biostatistician, with over 20 years of experience in clinical trial strategy design and analysis, particularly in liver disease [2][3] Group 2: Company Strategy and Goals - The company aims to enhance its clinical decision-making capabilities and align with regulatory requirements, focusing on innovative product offerings in a resource-limited disease area [2][4] - Yaqrit is actively pursuing financing channels and partnerships with pharmaceutical companies to advance its drug products into late-stage clinical trials, including YAQ006 and YAQ007 [2][4]